Registered Nurse
About the job
- A Bachelor of Science in Nursing from an ACEN- or CCNE-accredited institution and at least two years of relevant experience, or an Associate of Science in Nursing from an ACEN- or CCNE-accredited institution, two years of relevant experience, and enrollment to complete a Bachelor of Science in Nursing from an ACEN- or CCNE-accredited institution within three years of hire.
- A Florida Registered Nurse license.
- Advanced Cardiovascular Life Support certification.
- Use the nursing process to assess, plan, and evaluate care for cancer patients and families, integrating patient- and family-centered care and quality caring factors into practice.
- Identify, document, and provide patient education based on the patient's learning needs.
- Participate in evidence-based improvement activities related to the area of practice.
- Participate in professional development based on nursing professional standards, regulatory requirements, and job expectations.
- Strong intravenous skills.
- Three years of procedural recovery experience.
Working at Moffitt is both a career and a mission: to contribute to the prevention and cure of cancer.
As the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, Moffitt employs some of the best and brightest minds from around the world. Join a dedicated team of nearly 11,000 who are shaping the future we envision. Moffitt has been recognized as a Best and Brightest Company to Work For in the Nation and is continually named one of the Tampa Bay Times’ Top Workplaces.
Summary
To deliver individualized quality nursing care to cancer patients and families in accordance with established hospital guidelines, nursing professional practice model, nursing care standards and policies and in accordance with ANA code of ethics and external regulatory agencies.Registered Nurses embody the vision, mission, and philosophy of Moffitt Nursing and are committed to and accountable for personalized patient and family centered care and the concepts of Duffy's quality caring model/caring factors. These frameworks of care include: collaboration and mutual problem solving, dignity and human respect, encouraging manner, attentive reassurance, appreciation of unique meaning, healing environment, basic human needs, information sharing, caring for self, and affiliation needs. (see attached)Registered Nurses use the nursing process to effectively plan and manage quality patient care. Biophysical, psychosocial, environmental, self-care, educational and discharge planning needs are addressed in all steps of the nursing process. This is demonstrated in base-line and comparative documentation, entered in a timely manner, and with evidence of age-appropriate consideration when care is planned, delivered, and evaluated.The Professional Practice Model graphic and Duffy's caring factors are attached." An endoscopy is a minimally invasive procedure during which a gastroenterologist examines a patient’s digestive tract. At Moffitt Cancer Center, our gastroenterologists use endoscopy to diagnose and treat noncancerous, precancerous and cancerous conditions of the gastrointestinal tract. Our gastroenterologists have the experience necessary to treat complex and challenging cases as well as common diagnoses, and our individualized approach to treatment ensures that a one-of-a-kind plan is optimized for each patient’s unique needs. Depending on a patient’s diagnosis and the symptoms he or she is experiencing, our team might recommend any of the following endoscopic procedures: • Colonoscopy • Esophagogastroduodenoscopy (EGD) or upper endoscopy • Endoscopic ultrasound (EUS) • Endoscopic retrograde cholangiopancreatographies (ERCP) At Moffitt, all endoscopy based procedures are performed by experienced gastroenterologists who have specialized training in the field. Our gastroenterologists collaborate with the surgical oncologists, medical oncologists, radiation oncologists and supportive care providers to ensure that each patient’s unique needs are met. This multispecialty approach allows us to not only produce exceptional outcomes, but improve each patient’s quality of life throughout treatment and recovery. We are currently looking for a Registered Nurse to join our team. Position Highlights: • The Registered Nurse delivers individualized quality nursing care to cancer patients and families in accordance with established hospital guidelines, nursing professional practice model, nursing care standards and policies and in accordance with ANA code of ethics and external regulatory agencies. • Registered Nurses embody the vision, mission, and philosophy of Moffitt Nursing and are committed to and accountable for personalized patient and family centered care and the concepts of Duffy's quality caring model/caring factors. These frameworks of care include: collaboration and mutual problem solving, dignity and human respect, encouraging manner, attentive reassurance, appreciation of unique meaning, healing environment, basic human needs, information sharing, caring for self, and affiliation needs. • Registered Nurses use the nursing process to effectively plan and manage quality patient care. Biophysical, psychosocial, environmental, self-care, educational and discharge planning needs are addressed in all steps of the nursing process. This is demonstrated in base-line and comparative documentation, entered in a timely manner, and with evidence of age-appropriate consideration when care is planned, delivered, and evaluated. The Ideal Candidate • The ideal candidate will have the following qualifications: ◦ Strong IV skills ◦ 3 years of Procedural recovery Responsibilities: • Uses the nursing process to assess, plan, and evaluate the care of cancer patients and families. Integrates patient and family centered care and the quality caring factors into practice • Identifies, documents, and provides patient education based on learning needs of the patient • Participates in Evidence based improvement activities related to area of practice • Participates in professional development based on the nursing professionals standards, regulatory requirements, and job expectations Credentials and Qualifications: • BSN from an ACEN or CCNE accredited institution with at least two years of relevant experience or ASN from an ACEN or CCNE accredited institution with 2 years of relevant experience and enrolled to complete BSN from an ACEN or CCNE within 3 years of hire • FL RN License • ACLS Certification"Salary Range
$35.05 - $52.56Salary ranges posted for this position represent the expected base pay range for the role. Actual compensation may vary based on location and a variety of job-related factors, including experience, skills, education, and internal equity among Team Members in similar positions.
We are committed to maintaining fair and equitable pay practices and regularly review compensation to ensure alignment across our workforce.
If you have the vision, passion, and dedication to contribute to our mission,
then we have a place for you!
1. Equal Employment Opportunity
Moffitt Cancer Center is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, or protected veteran or disabled status. We seek candidates whose skills, and personal and professional experience, have prepared them to contribute to our commitment to diversity and excellence.
2. Reasonable Accommodation
Federal law requires employers to provide reasonable accommodation to qualified individuals with disabilities. Please tell us if you require a reasonable accommodation to apply for a job or to perform your job. Examples of reasonable accommodation include making a change to the application process or work procedures, providing documents in an alternate format, using a sign language interpreter, or using specialized equipment. Moffitt endeavors to make moffitt.org/careers accessible to any and all users. If you would like to contact us regarding the accessibility of our website or need assistance completing the application process, please contact one of the Human Resources receptionists by phone at 813-745-7899 or by email at [email protected]. This contact information is for accommodation requests only and cannot be used to inquire about the status of applications.
Read more information about your EEO rights under the law.
About the company
Moffitt Cancer Center is a health care organization focused on cancer prevention, treatment, research, and education in Tampa, Florida. It delivers patient care, conducts scientific research, and provides education to advance the fight against cancer. The center’s model combines direct cancer treatment with ongoing research and training to improve outcomes, rather than relying on a single service line or product. Its approach distinguishes it from others by integrating comprehensive clinical care with translational research and education, aiming to translate discoveries into better prevention, diagnosis, and therapies for patients. The goal is to reduce cancer incidence and improve survival by moving discoveries from the lab to the bedside and training the next generation of cancer specialists.
Company Size
5,001-10,000
Company Stage
Grant
Total Funding
$10K
Headquarters
Tampa, Florida
Founded
1984
Get referred to Moffitt Cancer Center
See people who can refer or advise you
Simplify's Take
What believers are saying
- Moffitt won $2.8 million federal funding on Sept. 10, 2026 for acral melanoma research.
- The July 27, 2026 proton therapy launch expands high-acuity radiation volume in Tampa Bay.
- The Polk County outpatient center adds Lakeland reach after the August 3 land buy.
What critics are saying
- Speros' $1.1 billion build exposes Moffitt to financing and execution slippage through 2029.
- The Polk center stays 2029-only, leaving competitors to capture local demand first.
- A referral-share loss to AdventHealth, Tampa General, or UF Health would weaken the whole model.
What makes Moffitt Cancer Center unique
- Moffitt is Florida’s only NCI-designated Comprehensive Cancer Center, anchoring referral gravity statewide.
- Its Speros campus pairs patient care, research, and a proton center in one hub.
- The 2026 Thyora spinout converts Moffitt science into owned drug-discovery assets.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Paid Time Off
- Parental Leave
Company News
The US Economic Development Administration has awarded a $47 million grant to a coalition led by Moffitt to build a radiopharmaceutical hub. The grant will fund five projects covering isotope production, drug manufacturing, and startup support, among other areas.
Novel HDAC inhibitor hits main goal in unresectable melanoma trial. - Four-month gain in PFS with HBI-8000, 13 months in LDH-normal subgroup, but toxicity a concern Progression-free survival (PFS) in unresectable melanoma improved significantly with the addition of an investigational histone deacetylase (HDAC) inhibitor to immunotherapy, a randomized trial showed. Median PFS increased from 7.36 months with nivolumab (Opdivo) and placebo to 11.66 months with nivolumab and HBI-8000. At 24 months, 41.3% of the combination arm remained alive and progression free compared with 28.7% of the control group. Patients with normal lactate dehydrogenase (LDH) levels at baseline, a majority of the study population, derived even more benefit from nivolumab-HBI-8000, with a median PFS of 20.04 months. Grade 3/4 treatment-related adverse events (TRAEs) occurred three times as often with nivolumab and HBI-8000 but were manageable in most cases, reported Nikhil Khushalani, MD, of Moffitt Cancer Center in Tampa, Florida, at the European Society for Medical Oncology congress in Madrid. "While GI [gastrointestinal] toxicities are certainly more common with this combination, these adverse events tend to be manageable with low rates of grade 3 and 4 nonhematologic adverse events," said Khushalani. "'The rate of endocrine toxicity appears similar to nivolumab alone. Combination HBI-8000 plus nivolumab can certainly be considered a standard-of-care option for advanced, unresectable melanoma, offering an advantage of oral dosing and potentially drug-specific dose attenuation for unique toxicities." The trial is clearly positive for the HDAC inhibitor-nivolumab arm, said ESMO invited discussant Olivier Michielin, MD, PhD, of Geneva University Hospital in Switzerland. The 2-year results compare favorably with 2-year results from two previous trials that established benchmarks for unresectable melanoma, CheckMate 067 (nivolumab with or without ipilimumab [Yervoy]) and RELATIVITY-047 (nivolumab alone or with relatlimab [Opdualag]). Two-year overall survival (OS) data for the earlier studies showed a nonsignificant trend favoring combination therapy, whereas 2-year OS data for the current study remain immature. "HDAC inhibitors clearly have an impact on cancer cells, promoting antigen presentation, but also making the cells more susceptible to immune killing," said Michielin. "There is also a wealth of impact on the tumor microenvironment, touching on all the cells, either directly or indirectly, and promoting generally a more immunostimulatory microenvironment, hence, a good rationale to combine these compounds with PD-1 blockade." "My personal take out of this abstract is that data could support HBI-8000 plus nivolumab as a first-line option, but the evolving dataset should be looked at carefully for OS but also toxicity in the coming months to really base our decision on the full package," he added. The phase III HBI-8000-303 trial followed a small phase Ib/II trial of the combination therapy in patients with anti-PD(L)1-naive advanced melanoma. The treatment led to an objective response rate of 65.8% with no unexpected toxicity. Conducted at 123 sites in 15 countries, the phase III trial enrolled 404 patients with unresectable stage III/IV melanoma and no prior exposure to a PD(L)1 inhibitor or any other immune checkpoint inhibitor. They were randomized to nivolumab with HBI-8000 or placebo and followed until disease progression or unacceptable toxicity. PFS was the primary endpoint. The patients had a median age of 67, and men accounted for 60-65% of the study population. Two-thirds of the patients had normal LDH levels at baseline, and about half had PD-L1-positive tumors. About 60% of the patients had clinical M0/M1a/M1b disease stage. After a median follow-up of 37 months, the primary analysis showed a 4.3-month difference in PFS in favor of the HBI-8000 arm, representing a 27% reduction in the PFS hazard (95% CI 0.56-0.95, P=0.0141). The subgroup analysis favored HBI-8000 for almost all patient categories. The PFS benefit with HBI-8000 in patients with normal LDH increased to 35% (CI 0.47-0.90, P=0.0082). PFS at 24 months showed a clear advantage for the HBI-8000 arm (41.3% vs 28.7% in all patients and 47.2% vs 32.6% in patients with normal LDH). Objective response rates were 41.4% versus 32.3%, a difference driven by a higher number of complete responses (14.3% vs 7.0%). Grade 3/4 TRAEs occurred in 54.8% of the HBI-8000 group and 17.9% of the placebo group. TRAE-related discontinuation rates were 14.1% with HBI-8000 and 5.0% in the control group. Notable differences in grade 3/4 hematologic TRAEs included thrombocytopenia (7.5% vs 0%) and neutropenia (16.6% vs 0.5%). Rates of pneumonitis, hyperthyroidism, and adrenal insufficiency were similar, including all-grade and grade 3/4.
Tampa Bay Wave collaborates with Vanderbilt Health to launch dual-region HealthTech|X Accelerator for Behavioral Health and Addiction startups. Collaboration pairs Tampa Bay and Nashville's healthcare ecosystems, giving founders direct access to investors, researchers, clinicians, and licensing opportunities. September 23, 2026 13:58 ET | Source: Tampa Bay Wave TAMPA, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) - Tampa Bay Wave, a nonprofit, zero-equity startup accelerator, today announced a new partnership with Vanderbilt Health through the Brock Family Center for Applied Innovation to power its 2026 HealthTech|X cohort. The dual-region program will support startups building technology for behavioral health and addiction, two of the fastest-growing and most urgent categories in the industry. Through the partnership, founders selected for the cohort will have direct access to Vanderbilt researchers, clinicians, informaticists and health system leaders, along with paths to clinical research partnerships, technology transfer and licensing of Vanderbilt technologies. "Behavioral health and addiction don't leave room for ideas that only work on paper. Founders need clinicians willing to test their technology against real patients, fast. That's what Vanderbilt brings to this partnership, and paired with everything we've built in Tampa Bay, it gives these founders a shot most Accelerators can't offer," said Linda Olson, Founder and CEO, Tampa Bay Wave. "Vanderbilt Health and the Brock Center for Applied Innovation are excited to collaborate with Tampa Bay Wave to welcome innovative behavioral health and addiction-focused startups into the HealthTech|X cohort. Together, we look forward to connecting founders with Nashville's vibrant healthcare innovation ecosystem and providing exposure to Vanderbilt's world-class clinical, research, and entrepreneurial resources to accelerate their business progress," said Ken Holroyd, MD, MBA, Director of Brock Family Center for Applied Innovation at Vanderbilt Health. "Behavioral health and addiction are two critical areas of healthcare that need innovation from strong founders. The opportunity to pair two of the strongest HealthTech ecosystems in the United States in Tampa and Nashville is unique and a major inflection point for the Tampa Bay Wave, but most importantly provides an opportunity to rally investors, healthcare executives, and more to support the incoming cohort companies in a big way as they grow and scale their startups," said Richard Munassi, MD, MBA, Managing Director, Tampa Bay Wave. "The entire Brock family and Brock Recovery Group team is excited to see the launch of the 2026 HealthTech|X Accelerator program focused on Behavioral Health and Addiction startups. With pairing together a world class Accelerator in the Tampa Bay Wave with all that Nashville and the Brock Family Center for Innovation at Vanderbilt Health has to offer, along with the tremendous ecosystems of Tampa and Nashville, the program will undoubtedly be of high value to all the matriculating startups, now and into the future," said Major Brock, CEO, Brock Recovery Group. The 2026 HealthTech|X cohort will run across both Tampa and Nashville, with in-person session weeks in each city and virtual engagement between them, culminating in pitch nights in each market and a remote Demo Day. Tampa Bay Wave collaborates with a broader ecosystem of healthcare partners, including Tampa General Hospital, BayCare, USF Health, Moffitt Cancer Center and the Tampa Medical Research District. About Tampa Bay Wave Tampa Bay Wave, Inc. is a 501(c)(3) nonprofit providing entrepreneurs with facilitated access to the resources, expertise and capital they need to grow vibrant technology-based companies in Tampa Bay. Since 2013, Tampa Bay Wave has supported more than 670 tech startups that have raised more than $2 billion in capital, created more than 7,600 jobs and completed 34 exits, driving an estimated $450 million in annual economic impact, thanks to grant funding from the U.S. Economic Development Administration (EDA), National Oceanic and Atmospheric Administration (NOAA), and the U.S. Small Business Administration (SBA), plus support from its economic development partners Hillsborough County, Pasco County, and the City of Tampa. Tampa Bay Wave also receives support from individuals, corporations and foundations such as: A-LIGN, Appspace, Bank of America, Celestar, Delta Air Lines/Virgin Atlantic Airlines, Florida High Tech Corridor, Foley & Lardner, Justworks, Kuducom, Nielsen Foundation, NextPath Workforce Solutions, St. Petersburg College, TECO, Thoropass, the University of South Florida and others. In 2026, Tampa Bay Wave was ranked the #3 accelerator in the U.S. and #1 in Florida by TIME. For more information, visit tampabaywave.org. About Vanderbilt Health Vanderbilt Health, a growing academic health system headquartered in Nashville, Tennessee, is one of the largest and most prominent academic systems in the Southeast, providing patient care, conducting research and training the next generation of health professionals. With 43,000 employees, including 4,930 employed clinicians, Vanderbilt Health accommodated more than 3.5 million patient visits last year at its eight hospitals and 180-plus clinic locations. In 2025, Vanderbilt Health contributed $22.13 billion to the regional economy while also providing more than $1 billion in total community benefit and investment including patient financial assistance, medical research, health professional education, community grants and unreimbursed costs for government health programs. For more information, visit VanderbiltHealth.com.
Moffitt Cancer Center opens new office in SW marion county. Ocala Star-Banner Sept. 11, 2026, 10:43 a.m. ET Moffitt Cancer Center welcomed guests and dignitaries to a ribbon cutting ceremony held Sept. 10 at its new southwest Ocala facility. Among the speakers at the Moffitt First Connect office, 11115 SW 93rd Court Road, Suite 600, was cancer survivor Amy Bondon. She said she felt blindsided by the diagnosis and her mind was racing with all of the possibilities. At Moffitt, Bondon said, she was greeted with a smile, treated well with kindness and empathy, and was embraced with love and care.
Copyright 1999-2024, Appraisal Development International, Inc. | Mon Aug 03 2026 16:07:08 GMT-0700 (Pacific Daylight Time) | | PO Box 1212 Tampa, FL 33601 Pinellas (727) 726-8811 Hillsborough (813) 258-5827 Toll Free 1-888-683-7538 Fax (813) 258-5902 TOOLS CONVERSION CHART STANDARD DEVIATION MORTGAGE CALCULATOR Updated November 2024 | / | RETURN TO NEWS INDEX Moffitt makes $12 million land buy for first Polk County outpost By Ashley Gurbal Kritzer Tampa Bay Business Journal Published: Aug 3, 2026 Moffitt Cancer Center has paid $12 million for the Lakeland property where it intends to open its first Polk County outpost. The Tampa-based health system closed on just over 34 acres along US Highway 98 in Lakeland on July 8, Polk County property records show. Moffitt previously announced that the new facility, which will offer outpatient treatment, would be supported in part by a $10 million donation from Wesley and Ashley Bell Barnett, along with a partial land donation from Steve, Dane and Tom Rogers and family. TO READ MORE CLICK HERE TAMPA BAY BUSINESS JOURNAL | INTRO | FAQ | RESIDENTIAL | COMMERCIAL | NEWS | RESOURCES | TOOLS | TEAM | CONTACT | CLIENTS LOGIN | PRIVACY | | Copyright 1999-2024, Appraisal Development International, Inc |